Hopfner Michael, Schuppan Detlef, Scherubl Hans
World J Gastroenterol. 2008 Dec 14;14(46):7021-32. doi: 10.3748/wjg.14.7021.
The limited efficacy of cytotoxic therapy for advanced biliary tract and gallbladder cancers emphasizes the need for novel and more effective medical treatment options. A better understanding of the specific biological features of these neoplasms led to the development of new targeted therapies, which take the abundant expression of several growth factors and cognate tyrosine kinase receptors into account. This review will briefly summarize the status and future perspectives of antiangiogenic and growth factor receptor-based pharmacological approaches for the treatment of biliary tract and gallbladder cancers. In view of multiple novel targeted approaches, the rationale for innovative therapies, such as combinations of growth factor (receptor)-targeting agents with cytotoxic drugs or with other novel anticancer drugs will be highlighted.
细胞毒性疗法对晚期胆管癌和胆囊癌的疗效有限，这凸显了对新型且更有效治疗方案的需求。对这些肿瘤特定生物学特征的深入了解促使了新的靶向疗法的开发，这些疗法考虑到了多种生长因子和相关酪氨酸激酶受体的大量表达。本综述将简要总结基于抗血管生成和生长因子受体的药物治疗方法在胆管癌和胆囊癌治疗中的现状及未来前景。鉴于多种新型靶向方法，将重点介绍创新疗法的理论依据，例如将生长因子（受体）靶向药物与细胞毒性药物或其他新型抗癌药物联合使用。
